News

Press releases

June 18, 2025

Atalanta Therapeutics Announces Leadership Transitions

April 8, 2025

Atalanta Therapeutics Publishes Preclinical Data Supporting Investigational RNAi Therapy for KCNT1-Related Epilepsy

January 28, 2025

Atalanta Therapeutics Closes Oversubscribed $97 Million Series B Financing to Advance Two RNAi Therapies for CNS Diseases to Clinical Trial

May 22, 2024

Atalanta Therapeutics Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial Officer

March 10, 2022

Atalanta Therapeutics Appoints Alfred Sandrock to Board of Directors

Presentations & Publications

2024

Durable Suppression of Spontaneous Seizures in a Mouse Model of KCNT1 Genetic...

Read More

2024

Widespread and Durable Knockdown of HTT in Non-Human Primate Brain...

Read More

2024

Long-Lasting Analgesia in Rodents by siRNA-Mediated Silencing of Nav1.7.

Read More

2024

Silencing Gain-of-Function KCNT1 Genetic Epilepsy with Divalent siRNA

Read More

Alterman JF, Godinho BMDC, Hassler MR, et al. A divalent siRNA chemical...

Read More

Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical...

Read More
Your browser is out of date!

Update your browser to view this website correctly. Update my browser now